In Silico screening for agonists and blockers of the β2 adrenergic receptor: Implications of inactive and activated state structures

Ten crystal structures of the β2 adrenergic receptor have been published, reflecting different signaling states. Here, through controlled‐docking experiments, we examined the implications of using inactive or activated structures on the in silico screening for agonists and blockers of the receptor. Specifically, we targeted the crystal structures solved in complex with carazolol (2RH1), the neutral antagonist alprenalol, the irreversible agonist FAUC50 (3PDS), and the full agonist BI‐167017 (3P0G). Our results indicate that activated structures favor agonists over blockers, whereas inactive structures favor blockers over agonists. This tendency is more marked for activated than for inactive structures. Additionally, agonists tend to receive more favorable docking scores when docked at activated rather than inactive structures, while blockers do the opposite. Hence, the difference between the docking scores attained with an activated and an inactive structure is an excellent means for the classification of ligands into agonists and blockers as we determined through receiver operating characteristic curves and linear discriminant analysis. With respect to virtual screening, all structures prioritized well agonists and blockers over nonbinders. However, inactive structures worked better for blockers and activated structures worked better for agonists, respectively. Notably, the combination of individual docking experiments through receptor ensemble docking resulted in an excellent performance in the retrieval of both agonists and blockers. Finally, we demonstrated that the induced‐fit docking of agonists is a viable way of modifying an inactive crystal structure and bias it toward the in silico recognition of agonists rather than blockers. © 2011 Wiley Periodicals, Inc. J Comput Chem, 2011

[1]  Cheng Zhang,et al.  Structure and Function of an Irreversible Agonist-β2 Adrenoceptor complex , 2010, Nature.

[2]  M. Bouvier,et al.  The evasive nature of drug efficacy: implications for drug discovery. , 2007, Trends in pharmacological sciences.

[3]  Brian K. Shoichet,et al.  Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.

[4]  Santiago Vilar,et al.  In silico analysis of the binding of agonists and blockers to the β2-adrenergic receptor. , 2011, Journal of molecular graphics & modelling.

[5]  L. Fabbri,et al.  Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents , 2010, Respiratory research.

[6]  Raymond C Stevens,et al.  Discovery of new GPCR biology: one receptor structure at a time. , 2009, Structure.

[7]  Robert J. Lefkowitz,et al.  G-protein-coupled Receptor Kinase Specificity for β-Arrestin Recruitment to the β2-Adrenergic Receptor Revealed by Fluorescence Resonance Energy Transfer* , 2006, Journal of Biological Chemistry.

[8]  Claudio N. Cavasotto,et al.  Ligand-Steered Modeling and Docking: A Benchmarking Study in Class A G-Protein-Coupled Receptors , 2010, J. Chem. Inf. Model..

[9]  Kenneth A Jacobson,et al.  Molecular architecture of G protein‐coupled receptors , 1996, Drug development research.

[10]  Ruben Abagyan,et al.  Identifying conformational changes of the β2 adrenoceptor that enable accurate prediction of ligand/receptor interactions and screening for GPCR modulators , 2009, J. Comput. Aided Mol. Des..

[11]  Charles L. Brooks,et al.  Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008 , 2009, Nature Reviews Drug Discovery.

[12]  S. Gygi,et al.  Global phosphorylation analysis of β-arrestin–mediated signaling downstream of a seven transmembrane receptor (7TMR) , 2010, Proceedings of the National Academy of Sciences.

[13]  Santiago Vilar,et al.  Ligand and structure‐based models for the prediction of ligand‐receptor affinities and virtual screenings: Development and application to the β2‐adrenergic receptor , 2009, J. Comput. Chem..

[14]  Yang Xiang,et al.  Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states. , 2004, The Journal of biological chemistry.

[15]  S. Rasmussen,et al.  Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.

[16]  Jonathan S. Mason,et al.  Progress in Structure Based Drug Design for G Protein-Coupled Receptors , 2011, Journal of medicinal chemistry.

[17]  Brian K. Kobilka,et al.  Cloning of the gene and cDNA for mammalian β-adrenergic receptor and homology with rhodopsin , 1986, Nature.

[18]  Jeremy R. Greenwood,et al.  Epik: a software program for pKa prediction and protonation state generation for drug-like molecules , 2007, J. Comput. Aided Mol. Des..

[19]  J L Benovic,et al.  The multiple membrane spanning topography of the beta 2-adrenergic receptor. Localization of the sites of binding, glycosylation, and regulatory phosphorylation by limited proteolysis. , 1987, The Journal of biological chemistry.

[20]  Ruben Abagyan,et al.  Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.

[21]  Robert J. Lefkowitz,et al.  β-Arrestin-biased Agonism at the β2-Adrenergic Receptor* , 2008, Journal of Biological Chemistry.

[22]  D. Rognan,et al.  Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor. , 2008, Journal of medicinal chemistry.

[23]  David Calkins,et al.  Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution , 2010, J. Comput. Aided Mol. Des..

[24]  S. Rasmussen,et al.  The structure and function of G-protein-coupled receptors , 2009, Nature.

[25]  Xavier Deupi,et al.  Conformational complexity of G-protein-coupled receptors. , 2007, Trends in pharmacological sciences.

[26]  S. Green,et al.  A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. , 1993, The Journal of biological chemistry.

[27]  Claudio N. Cavasotto and Narender Singh Docking and High Throughput Docking: Successes and the Challenge of Protein Flexibility , 2008 .

[28]  R. Lefkowitz,et al.  New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors. , 2006, Molecular cell.

[29]  R. Abagyan,et al.  Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. , 2010, Journal of the American Chemical Society.

[30]  Robert J. Lefkowitz,et al.  G Protein-coupled Receptors , 1998, The Journal of Biological Chemistry.

[31]  Stefano Costanzi,et al.  Rhodopsin and the others: a historical perspective on structural studies of G protein-coupled receptors. , 2009, Current pharmaceutical design.

[32]  Sudarshan Rajagopal,et al.  Quantifying Ligand Bias at Seven-Transmembrane Receptors , 2011, Molecular Pharmacology.

[33]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[34]  Stefano Costanzi,et al.  On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor. , 2008, Journal of medicinal chemistry.

[35]  R. Stevens,et al.  GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function , 2007, Science.

[36]  R. Friesner,et al.  Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.

[37]  Claudio N. Cavasotto,et al.  Docking-based virtual screening for ligands of G protein-coupled receptors: not only crystal structures but also in silico models. , 2011, Journal of molecular graphics & modelling.

[38]  Ja Johnson,et al.  Cardiovascular Pharmacogenomics of Adrenergic Receptor Signaling: Clinical Implications and Future Directions , 2011, Clinical pharmacology and therapeutics.

[39]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[40]  Ruben Abagyan,et al.  GPCR 3D homology models for ligand screening: Lessons learned from blind predictions of adenosine A2a receptor complex , 2010, Proteins.

[41]  Stefano Costanzi,et al.  Modeling G Protein-Coupled Receptors: a Concrete Possibility. , 2010, Chimica oggi.

[42]  P. Marin,et al.  GPCR interacting proteins (GIP). , 2004, Pharmacology & therapeutics.

[43]  Xavier Deupi,et al.  Coupling ligand structure to specific conformational switches in the β2-adrenoceptor , 2006, Nature chemical biology.

[44]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..